نتائج البحث - "D. R. D'Adamo"

1

Eribulin Plus Pembrolizumab in Patients with Metastatic Triple-Negative Breast Cancer (ENHANCE 1): A Phase Ib/II Study

المؤلفون: Peter A. Kaufman, Ella Kleynerman, Claudio Savulsky, Virginia G. Kaklamani, Sharon Wilks, Michaela L. Tsai, Grace Wang, Yuan Yuan, Dongyuan Xing, D. R. D'Adamo, Gursel Aktan, Eleni Andreopoulou, Debra A. Patt, Ruth O'Regan, Sara M. Tolaney, Sami Diab, Kevin Kalinsky, Vassiliki Karantza

المصدر: Clinical cancer research : an official journal of the American Association for Cancer Research. 27(11)

مصطلحات موضوعية: Oncology, Adult, Cancer Research, medicine.medical_specialty, Nausea, medicine.medical_treatment, Gene Expression, Triple Negative Breast Neoplasms, Pembrolizumab, Antibodies, Monoclonal, Humanized, B7-H1 Antigen, 03 medical and health sciences, chemistry.chemical_compound, 0302 clinical medicine, Breast cancer, Internal medicine, Antineoplastic Combined Chemotherapy Protocols, Biomarkers, Tumor, Medicine, Humans, 030212 general & internal medicine, Adverse effect, Furans, Infusions, Intravenous, Triple-negative breast cancer, Aged, Aged, 80 and over, Chemotherapy, business.industry, Ketones, Middle Aged, medicine.disease, Treatment Outcome, chemistry, Tolerability, 030220 oncology & carcinogenesis, Female, medicine.symptom, Safety, business, Eribulin

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d18ff08c7305436447d9f5e35e7471a1Test
https://pubmed.ncbi.nlm.nih.gov/33727258Test

2

Activity of Eribulin in Patients With Advanced Liposarcoma Demonstrated in a Subgroup Analysis From a Randomized Phase III Study of Eribulin Versus Dacarbazine

المؤلفون: D. R. D'Adamo, Giovanni Grignani, George D. Demetri, Brian A. Van Tine, Robert G. Maki, Patrick Schöffski, Robin L. Jones, Sant P. Chawla, Thierry Alcindor, Matthew Guo, Jean-Yves Blay

المصدر: Journal of Clinical Oncology. 35:3433-3439

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7d7d40b11e3e6797cbda0f18084252abTest
https://doi.org/10.1200/jco.2016.71.6605Test

3

Eribulin versus dacarbazine in patients with leiomyosarcoma : subgroup analysis from a phase 3, open-label, randomised study

المؤلفون: Yan Jia, Sebastian Bauer, D. R. D'Adamo, Jean-Yves Blay, Robert G. Maki, Anders Krarup-Hansen, Patrick Schöffski, Charlotte Benson

المصدر: British Journal of Cancer
Blay, J Y, Schöffski, P, Bauer, S, Krarup-Hansen, A, Benson, C, D’Adamo, D R, Jia, Y & Maki, R G 2019, ' Eribulin versus dacarbazine in patients with leiomyosarcoma : subgroup analysis from a phase 3, open-label, randomised study ', British Journal of Cancer, vol. 120, no. 11, pp. 1026-1032 . https://doi.org/10.1038/s41416-019-0462-1Test

مصطلحات موضوعية: Leiomyosarcoma, Eribulin Mesylate, Adult, Male, Cancer Research, medicine.medical_specialty, Dacarbazine, Medizin, Phases of clinical research, MESYLATE, Subgroup analysis, Gastroenterology, Article, 03 medical and health sciences, chemistry.chemical_compound, 0302 clinical medicine, PROGNOSTIC-FACTORS, Internal medicine, SURVEILLANCE, medicine, EPIDEMIOLOGY, Humans, MESILATE, Prospective Studies, Furans, Aged, Science & Technology, business.industry, Hazard ratio, SITE, Sarcoma, Ketones, Middle Aged, medicine.disease, E7389, Gemcitabine, SOFT-TISSUE SARCOMA, chemistry, Oncology, GEMCITABINE, 030220 oncology & carcinogenesis, Female, business, Life Sciences & Biomedicine, Eribulin, medicine.drug

وصف الملف: Print-Electronic; application/pdf

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c3b983b26448ddfa2191674e474512fcTest
https://www.ncbi.nlm.nih.gov/pubmed/31065111Test

4

A Phase II Trial of Sorafenib and Dacarbazine for Leiomyosarcoma, Synovial Sarcoma, and Malignant Peripheral Nerve Sheath Tumors

المؤلفون: Richard D. Carvajal, Robert A. Lefkowitz, Li-Xuan Qin, Mary Louise Keohan, Robert G. Maki, D. R. D'Adamo, Mark A. Dickson, William D. Tap, Marietta O. Ezeoke, Catherine M. Hirst, Martee L. Hensley, Gary K. Schwartz, Linda Ahn, Cristina R. Antonescu

مصطلحات موضوعية: 0301 basic medicine, Leiomyosarcoma, Sorafenib, Oncology, Adult, Male, Cancer Research, medicine.medical_specialty, medicine.medical_treatment, Dacarbazine, Phases of clinical research, Administration, Oral, Severity of Illness Index, Drug Administration Schedule, 03 medical and health sciences, Sarcoma, Synovial, 0302 clinical medicine, Internal medicine, Antineoplastic Combined Chemotherapy Protocols, medicine, Humans, Response Evaluation Criteria in Solid Tumors, Aged, Febrile Neutropenia, Aged, 80 and over, Chemotherapy, Dose-Response Relationship, Drug, business.industry, Soft tissue sarcoma, Sarcomas, Middle Aged, medicine.disease, Synovial sarcoma, Progression-Free Survival, 030104 developmental biology, Neurofibrosarcoma, 030220 oncology & carcinogenesis, Feasibility Studies, Female, Sarcoma, business, medicine.drug

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b3b3deae429d6e5b6ccade4d7519f045Test
https://europepmc.org/articles/PMC6656505Test/

5

A phase Ib/II study of eribulin (ERI) plus pembrolizumab (PEMBRO) in metastatic triple-negative breast cancer (mTNBC) (ENHANCE 1)

المؤلفون: Vassiliki Karantza, Sharon Wilks, Michaela L. Tsai, Dongyuan Xing, Grace Wang, Debra A. Patt, Yuan Yuan, D. R. D'Adamo, Sara M. Tolaney, Kevin Kalinsky, Peter A. Kaufman, Gursel Aktan, Virginia G. Kaklamani, Sami Diab, Ella Kleynerman, Eleni Andreopoulou, Ruth O'Regan

المصدر: Journal of Clinical Oncology. 38:1015-1015

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_________::30620c50e8a579525a17259a386d4dedTest
https://doi.org/10.1200/jco.2020.38.15_suppl.1015Test

6

A phase I/II study of eribulin mesilate (ERI) plus irinotecan (IRI) in children with refractory or recurrent solid tumors

المؤلفون: Ana Sastre Urgelles, Rachael Scott, Christof M. Kramm, Franco Locatelli, Yan Jia, Udo Kontny, Francisco Bautista, D. R. D'Adamo, Michela Casanova, Claudio Favre, Jagadeesh Aluri, Raquel Hladun Alvaro, Dirk Reinhardt

المصدر: Journal of Clinical Oncology. 38:10535-10535

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::201c34c06f4f37219c89cffe16e24026Test
https://doi.org/10.1200/jco.2020.38.15_suppl.10535Test

7

A phase 1 study of eribulin mesylate (E7389), a novel microtubule targeting chemotherapeutic agent, in children with refractory or recurrent solid tumors: a Children’s Oncology Group Phase 1 Consortium study (ADVL1314)

المؤلفون: D. R. D'Adamo, Charles G. Minard, Rachael Scott, Sandhya Devarajan, Gresel Martinez, Joel M. Reid, Susan M. Blaney, Eric S. Schafer, Stacey L. Berg, Rachel E. Rau, Brenda J. Weigel, Xiaowei Liu, Larisa Reyderman, Elizabeth Fox

مصطلحات موضوعية: 0301 basic medicine, Eribulin Mesylate, Oncology, Male, medicine.medical_specialty, Adolescent, Maximum Tolerated Dose, Nausea, Antineoplastic Agents, Neutropenia, Microtubules, Article, 03 medical and health sciences, chemistry.chemical_compound, 0302 clinical medicine, Refractory, Pharmacokinetics, Internal medicine, Neoplasms, Medicine, Humans, Child, Furans, Dose-Response Relationship, Drug, business.industry, Hematology, Ketones, medicine.disease, Hypokalemia, 030104 developmental biology, chemistry, Drug Resistance, Neoplasm, 030220 oncology & carcinogenesis, Child, Preschool, Pediatrics, Perinatology and Child Health, Toxicity, Female, medicine.symptom, Neoplasm Recurrence, Local, business, Eribulin

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1d90cf670a6c5f8e0d066ebf3bf3cb9bTest
https://europepmc.org/articles/PMC6019176Test/

8

Eribulin versus dacarbazine in previously treated patients with advanced liposarcoma or leiomyosarcoma: a randomised, open-label, multicentre, phase 3 trial

المؤلفون: Shreyaskumar Patel, Jean-Yves Blay, Sebastian Bauer, Axel Le Cesne, Patrick Schöffski, Sun Young Rha, George D. Demetri, D. R. D'Adamo, Robert G. Maki, Antoine Italiano, Giovanni Grignani, Matthew Guo, Peter Hohenberger, Bartosz Chmielowski, Veridiana Pires de Camargo, Sant P. Chawla, Hans Gelderblom, Edwin Choy

المساهمون: Department of General Medical Oncology [Leuven], University Hospitals Leuven [Leuven], Sarcoma Oncology Center, Sarcoma program, New York University [New York] (NYU), NYU System (NYU)-NYU System (NYU), Service de Pathologie, Institut Bergonié [Bordeaux], UNICANCER-UNICANCER, Leids Universitair Medisch Centrum [Leiden, The Netherlands], Universität Duisburg-Essen [Essen], Centre Léon Bérard [Lyon], Centre de Recherche en Cancérologie de Lyon (UNICANCER/CRCL), Centre Léon Bérard [Lyon]-Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon-Centre National de la Recherche Scientifique (CNRS)-Institut National de la Santé et de la Recherche Médicale (INSERM), Département de médecine oncologique [Gustave Roussy], Institut Gustave Roussy (IGR), Department of Cancer Biology, Dana-Farber Cancer Institute [Boston], New York University [New York], Institut Bergonié, Centre de Recherche en Cancérologie de Lyon ( CRCL ), Centre Léon Bérard [Lyon]-Université Claude Bernard Lyon 1 ( UCBL ), Université de Lyon-Université de Lyon-Institut National de la Santé et de la Recherche Médicale ( INSERM ) -Centre National de la Recherche Scientifique ( CNRS ), Institut Gustave Roussy ( IGR )

المصدر: Lancet
Lancet, Elsevier, 2016, 387 (10028), pp.1629-1637. ⟨10.1016/S0140-6736(15)01283-0⟩
Lancet, Elsevier, 2016, 387 (10028), pp.1629-1637. 〈http://linkinghub.elsevier.com/retrieve/pii/S0140673615012830Test〉. 〈10.1016/S0140-6736(15)01283-0〉
Lancet, 387(10028), 1629-1637

مصطلحات موضوعية: Male, 0301 basic medicine, Leiomyosarcoma, Survival, Medizin, Phases of clinical research, Soft Tissue Neoplasms, Medical Oncology, [ SDV.CAN ] Life Sciences [q-bio]/Cancer, surgery, chemistry.chemical_compound, 0302 clinical medicine, Belgium, Germany, Clinical endpoint, Aged, 80 and over, education.field_of_study, Hazard ratio, Sarcoma, General Medicine, Liposarcoma, Ketones, Middle Aged, 3. Good health, Dacarbazine, Treatment Outcome, Tolerability, Italy, 030220 oncology & carcinogenesis, Disease Progression, Medicine, Female, France, Brazil, Eribulin, medicine.drug, Adult, medicine.medical_specialty, Patients, Population, Antineoplastic Agents, [SDV.CAN]Life Sciences [q-bio]/Cancer, methods, Young Adult, 03 medical and health sciences, Internal medicine, medicine, Humans, Furans, education, Antineoplastic Agents, Alkylating, Survival analysis, Aged, business.industry, Survival Analysis, Surgery, 030104 developmental biology, chemistry, Neoplasm Grading, business

وصف الملف: Print-Electronic; application/pdf

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::41a1d0d83df5b6ad8e421e4b7b52dc32Test
https://hdl.handle.net/1887/112895Test

9

Phase II Trial of Gemcitabine and Docetaxel with Bevacizumab in Soft Tissue Sarcoma

المؤلفون: Sandra P. D'Angelo, Mrinal M. Gounder, Gary K. Schwartz, D. R. D'Adamo, Li-Xuan Qin, Mary Louise Keohan, Robert A. Lefkowitz, Robert G. Maki, Olivia R. McKennon, Catherine M. Hirst, Richard D. Carvajal, Mark A. Dickson, William D. Tap

المصدر: Sarcoma, Vol 2015 (2015)
Sarcoma

مصطلحات موضوعية: Oncology, medicine.medical_specialty, Bevacizumab, Article Subject, business.industry, Soft tissue sarcoma, medicine.disease, Bioinformatics, lcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogens, lcsh:RC254-282, Gemcitabine, Docetaxel, Internal medicine, medicine, Radiology, Nuclear Medicine and imaging, Sarcoma, business, medicine.drug, Research Article

وصف الملف: text/xhtml

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::864adceb94a11b1d3792ae0236697ec9Test
https://doaj.org/article/cd110dda17d64e1596ed55225f2f7a45Test

10

Subgroup analysis of leiomyosarcoma patients from a phase 3, open-label, randomized study of eribulin versus dacarbazine in patients with advanced liposarcoma or leiomyosarcoma

المؤلفون: Sebastian Bauer, Patrick Schöffski, D. R. D'Adamo, Robert G. Maki, J.-Y. Blay, Charlotte Benson, Matthew Guo, Anders Krarup-Hansen

المصدر: European Journal of Cancer. 72:S155

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_________::452c0d03c23cb69f180346c8eba42a62Test
https://doi.org/10.1016/s0959-8049Test(17)30581-6

تنقيح النتائج